Presence of Phosphorylated Tau Protein in the Skin of Alzheimer’s Disease Patients

Rodríguez-Leyva Ildefonso1,5, Chi-Ahumada Erika2, Calderón–Garcidueñas Ana Laura3, Medina-Mier Verónica1, Santoyo Martha E2, Martel-Gallegos Guadalupe4, Zarazúa Sergio6, Carrizales Juan2 and Jiménez-Capdeville María E2

1Department of Neurology, Central Hospital “Ignacio Morones Prieto”, San Luis Potosi, Mexico
2Department of Biochemistry, Faculty of Medicine, Universidad Autónoma de San Luis Potosi, Mexico
3Institute of Forensic Medicine, Universidad Veracruzana, Boca del Río, Mexico
4Laboratory of Neurotoxicology, Faculty of Chemistry, Universidad Autónoma de San Luis Potosi, Mexico
5Graduate program in Applied Sciences, Universidad Autónoma de San Luis Potosi, Mexico
6*Corresponding author: Jiménez-Capdeville, ME Faculty of Medicine, University of San Luis Potosi. Av. V. Carranza 2405 Col. Los Filtros, 78210 San Luis Potosi, SLP, Mexico, Tel: +52 (444) 826 23 00, Ext: 6630, E-mail: mejimenez@uaslp.mx

Abstract

Background: The presence of misfolded proteins in the brain is the hallmark of neurodegenerative diseases. Protein aggregates could have systemic expression and might be found in several tissues including the skin.

Objective: To demonstrate the presence of phosphorylated Tau (p-Tau) in the skin cells of patients with Alzheimer’s Disease (AD).

Material and methods: Antibodies against p-Tau (PHF, phosphorylated at S296 and AT8, phosphorylated at S202) were assayed in biopsied tissue from the retro-auricular area in 49 subjects: 20 with AD, 12 with non-degenerative dementia and 17 age-matched controls. Light and confocal microscopies were employed to localize Tau protein by immunohistochemistry and their presence in the skin was confirmed through Western blots.

Results: The skin biopsy taken from AD patients presented significantly higher levels of p-Tau (AT8: hyperphosphorylated at Ser 202) when compared both to control subjects and patients with non-degenerative dementia (p<0.001).

Conclusion: This study demonstrates the presence of p-Tau in skin biopsies by immunoreactivity. This procedure could be used to support the clinical diagnosis of AD in living patients.

Keywords: Alzheimer’s disease; Tau protein; Tau phosphorylation; Alzheimer’s disease diagnosis; Neurodegenerative diseases

Introduction

The increase in life expectancy of the population is associated with a higher incidence of neurodegenerative diseases. Their main feature is the expression of misfolded proteins [1-3]. The clinical differentiation among them is not always easy, since different proteinopathies can be expressed simultaneously. They are accompanied clinically by dementia, parkinsonism and/or motor dysfunction [4-9]. Currently, the definite diagnosis can only be done either demonstrating misfolded proteins in brain tissue or with genetic testing. Nevertheless, these proteins are also expressed outside the brain, not only in the peripheral nervous system but in the case of α-synuclein, also in other tissues such as the heart, gut and skin [10,11]. Tau is also expressed in skeletal muscle, lungs and kidneys. This opens the possibility of detecting proteinopathies in extra-cerebral tissues [12].

The brain and skin both share an ectodermal origin and therefore it is plausible to find molecular pathological alterations taking place in the skin as in the central nervous system. Since α-synuclein aggregates have been recently demonstrated in peripheral nerve terminals, epidermis and skin appendages of Parkinson’s disease (PD) patients [13-15], our objective was to demonstrate the usefulness of demonstrating protein aggregates in the skin cells as a potential biomarker for AD living patients. For this purpose, phosphorylated Tau aggregates were analyzed by immunohistochemistry in the skin of patients with Alzheimer (AD) and non-degenerative dementia (NDD). These groups were compared with a control group with similar demographic characteristics.

Materials and Methods

Reagents and antibodies

Reagents were analytical grade and the solutions were prepared in molecular grade water (18.2 Ω/cm). The following primary antibodies were employed: 1) rabbit monoclonal anti-tau (pSer396) [E178] (ab32057, Abcam, Cambridge, MA), which according to the supplier’s instructions detects both phosphorylated and non-phosphorylated tau and 2) Mouse monoclonal anti-tau (pSer202-pThr205) [AT8] (MN1020, Thermo Scientific, Rockford, IL). A biotinylated secondary antibody was obtained from DAKO (Carpinteria, CA) and for immunofluorescence we employed a goat anti-mouse IgG antibody.
marked with Alexa Fluor 488 and a goat anti-rabbit IgG antibody marked with Cy5 (A1101 and A10523, Molecular Probes, Eugene, OR). Cellular nuclei were evidenced with an orange nucleic acid stain, Sytox (S-11368, Molecular Probes, Eugene, OR). Western blot reagents were molecular biology grade and obtained from IBI Scientific (Peosta, IA, USA); except for bis-acrylamide and molecular weight markers, which were obtained from BioRad (Hercules, CA, USA).

Patient selection

The patients were selected from the Neurology Department external practice in the Central Hospital in San Luis Potosi, Mexico, and all the participants or their tutors signed an informed consent letter. The Institutional Ethics and Research Committee previously authorized the protocol. The inclusion criteria were being diagnosed with AD, a non-neurodegenerative dementia or to be an apparently healthy asymptomatic subject who accepted to participate in this study. Three groups of patients were studied 1) Healthy subjects with similar age and demographic characteristics to the rest of the participants 2) Patients with a probable AD diagnosis according to the NINCDS-ARDA criteria [16] and 3) Subjects with a diagnosis of a non-degenerative dementia (NND) (normotensive hydrocephalous, subdural hematoma post-traumatic dementia, vascular dementia and epilepsy). The exclusion criteria were 1) patients with a local or systemic infectious process; 2) Severely impaired coagulation and 3) not accepting to be part of the study.

All AD and NDD subjects underwent cranial CT or MRI to aid their diagnosis; it was not a requisite for the control group.

Tissue sampling and processing

The participants were biopsied by a punch of 4 mm, taking a skin sample 3 cm behind the ear insertion, with previous local anesthesia and aseptic cleaning of the region, followed by compression for hemostasis. The biopsies were immersed in 0.1 M phosphate buffer containing 4% paraformaldehyde during 24 h and embedded in paraffin. Coronal 5 μm sections were collected in electro-charged paraffin. Coronal 5 μm sections were collected in electro-charged paraffin. Coronal 5 μm sections were collected in electro-charged paraffin. Coronal 5 μm sections were collected in electro-charged paraffin. Sections then underwent incubation steps (15 min each) in a humidity chamber at room temperature to block unspecific background staining (Background sniper, Biocare Medical, LLC, Concord, CA) and blocked with 3% bovine serum albumin (BSA) in Tris-buffered saline (pH 7.6) containing 0.1% Tween (TBST) and probed overnight at 4°C with PHF-Tau (1:500) and AT8 (1:250). In addition, all membranes were probed with an antibody directed against β-actin as a control protein in whole lysates. After washing with TBST, the membranes were incubated with secondary antibodies HRP-conjugated (1:5000) in TBST+3% BSA during 1h 30 min. After subsequent washes, bands were visualized by chemiluminescence (Pierce, Rockford, IL USA) followed by autoradiography.

Western blot

Fifty mg of rat brain or human skin were processed obtaining 150-500 μg of total protein by homogenization with a lysis buffer (0.025 M Tris, 0.15M NaCl, 0.001M EDTA, 1% NP-40 and 5% glycerol) at pH 7.4 and supplemented with a protease and phosphatase inhibitor cocktail (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The supernatant was recovered by centrifugation at 12000 x g 10 min. Total protein was quantified by BCA assay. 50-80 μg were suspended in Laemli buffer 2X supplemented with 10% β-mercaptoethanol, boiled 10 min at 95°C and run on SDS-PAGE 10-15% gel. The proteins were electrophoretically transferred to 0.2 μm PVDF membranes (BioRad Laboratories, Hercules, CA) and blocked with 3% bovine serum albumin (BSA) in Tris-buffered saline (pH 7.6) containing 0.1% Tween (TBST) and probed overnight at 4°C with PHF-Tau (1:500) and AT8 (1:250). In addition, all membranes were probed with an antibody directed against β-actin as a control protein in whole lysates. After washing with TBST, the membranes were incubated with secondary antibodies HRP-conjugated (1:5000) in TBST+3% BSA during 1h 30 min. After subsequent washes, bands were visualized by chemiluminescence (Pierce, Rockford, IL USA) followed by autoradiography.

Evaluation and statistical analysis

The conformation of the three groups was made with the clinical presentation, MMSE, laboratory and image features. The pathologist was blind about the clinical diagnosis. In order to validate the evaluation procedure, 5 fields per section were captured at the same magnification (40X) and the immunopositive and immunonegative cells were manually counted using the Photoshop software (V 12.1 Adobe Systems Inc, San Jose CA) in the obtained color images; this quantification was finally expressed in percentage for each one of the participants (Figure 1A).
The quantification of immunopositivity, estimated by manual cell counting performed by two separated observers was compared, obtaining a 95% of correlation (Figure 1B). To corroborate these estimates and to obtain a confident and unbiased evaluation we also used a digital image processing. We employed the numerical principles from the model RGB (red, green, blue); 5 images from each sample of skin were evaluated, quantifying the total area and the expression of immunopositivity (Figure 1C). The images were processed by means of the commercial software Image Pro Plus 7 (MediaCybernetics, Bethesda, MD, USA). The kappa coefficient between the two employed methods was 0.8.

### Results

Control subjects and patient were in the same age range (p=0.7). The control group was confirmed by 17 subjects without neurological disease (normal MMSE); 20 patients with AD (mean MMSE 14) constituted the second group and individuals that presented non degenerative dementias (mean MMSE 17) constituted the third group of 12 subjects (Table 1). Significant differences among groups were found in MMSE scores between AD and control (p<0.001) and the NDD and control group (p<0.001).

The employed antibodies were previously tested in autopsied brain tissue from a confirmed AD cadaver. Both anti-tau antibodies reacted positively with cortical and hippocampal neurons presenting neurofibrillar tangles (Figure 2A and 2B). Both Anti-AT8 and anti – PHF antibodies showed immunoreactivity localized to the cytoplasm of the affected neurons, and in the neuropil of the cortical and hippocampal regions. Next, the immunoreactivity pattern in control skin biopsies was analyzed. Abundant cytoplasmic positivity and significant. Percentages of immunopositivity were subjected to a non-parametric analysis by means of Kruskal-Wallis test followed by U-Mann Whitney to make the comparison between groups.

---

**Table 1:** Significant differences among groups were found in MMSE scores and % immunopositivity for AT8. A p<0.001 as compared with the control group, B p<0.001 as compared with the AD group. ANOVA followed by Tuckey test for the variables age and MMSE. Kruskal-Wallis followed by Mann-Whitney U-test for immunopositivity percentages.

| Condition                        | Number of Subjects | Male/ Female | Age (Years, Mean ± SD) | MMSE (Points, Mean ± SD) | Immunopositivity percentage (median, min -max) |
|----------------------------------|--------------------|--------------|------------------------|--------------------------|-----------------------------------------------|
| Healthy                          | 17                 | 6/11         | 72 ± 14                | 29.4 ± 1.4               | 38 (9-58)                                     |
| Alzheimer’s disease              | 20                 | 8/12         | 79 ± 9                 | 14.5 ± 7.3               | 46 (9-67)                                     |
| Non-degenerative dementia        | 12                 | 9/3          | 76 ± 13                | 17.2 ± 9.7               | 46 (18-58)                                    |

---

**Figure 2:** Immunohistochemistry. Hippocampal neurons, PHF (A) and AT8 (B) with neurofibrillary tangles, in an AD patient, 100X, diaminobenzidine staining. Immunoreactivity patterns in epidermis of a control patient (C-D) and AD patient (E-F), with PHF and AT8 antibodies. 40X, amine-ethyl-carbazole staining.

---

**Figure 3:** Immunohistochemistry patterns in skin appendages of an AD patient. AT8 antibody showed juxtanuclear staining in the pilosebaceous unit and eccrine glands. Amine-ethyl-carbazole staining. 40 X.
scarce positive nuclear staining was observed in epidermal cells with PHF antibody (Figure 2C), nerve twigs were also stained. Null to scarce immunopositivity was detected to the AT8 epitope in control subjects (Figure 2D). In the skin from AD (Figure 2E) a clear PHF-positivity was demonstrated.

Also, in AD patients (Figure 2F) we found juxtanuclear red expression, with granular staining involving keratinocyte nuclei throughout the thickness of the epidermis with AT8 antibody. When the skin appendages were evaluated (Figure 3), the pilosebaceous unit (PSU) of AD patients showed a strong red juxtanuclear immunopositivity to PHF and AT8 in both, PSU (A,C) and eccrine gland (B,D). PHF antibody stained the cytoplasm of eccrine gland cells intensely, while cell nuclei were immunopositive to AT8 [17]. The nuclear and juxtanuclear localization of abundant AT8 immunopositivity in AD patients was confirmed by immunofluorescence (Figure 4F), while the PHF epitope showed immunopositivity both in control (4A) and AD patients (4E), with a predominant cytoplasmic localization (Figure 4A and 4E).

The localization of the granules was confirmed with the staining to delineate nuclei in red (Sytox, Figure 4C and 4G) and by merging the images from both antibodies. A clearly different pattern of immunofluorescence between controls and patients is observed in these images, marked by a difference in AT8 immunostaining (Figures 4D and 4H). The comparative analysis of the control group with AD patients showed that controls presented sparse, green, juxtanuclear granules in few keratinocytes with AT8 antibody (Figure 4B); versus frequent juxtanuclear green granules in AD patients (Figure 4F). The presence of positivity to AT8 in keratinocytes was clear in the merged image (Figure 4H). The identity of p-Tau in human skin was confirmed through Western blots (Figure 5).

Although protein aggregates were detected in the different epidermis strata and skin appendages, the structure that allowed an in depth analysis and comparison of protein immunoreactivity was the epidermis (Figure 6). Immunoreactivity to PHF antibodies was similar in the 3 groups of patients showing not statistically significant difference \( [H(2, N=49)=5.1, p=0.08] \). By contrast, immunoreactivity to AT8 antibodies was significantly different among groups \( [H(2, N=49)=35.8, p<0.001] \). The analysis between groups showed that AD patients presented significantly higher AT8 immunoreactivity than controls and patients suffering from non-degenerative dementias \( (p<0.001) \).
Discussion

A skin biopsy was taken from a sample of 49 subjects with similar demographic characteristics. When we compared the group of AD, this presented significantly higher levels of p-Tau (AT8: hyperphosphorylated at Ser 202) than both control and non-degenerative dementia group. These antibodies were chosen because in human studies, Ser396 phosphorylation (PHF) has been reported as an event that starts early in neurodegeneration and increases with aging and with the disease progress. Phosphorylation at Ser202 on the other hand is always present and significantly increased in diseased brains when compared to controls [18].

These phosphorylation sites have also been reported in the reversible tau hyperphosphorylation that takes place in hibernating animals proposed as a model for the study of taupathies. In this model, both sites (S396 and S202) present an important increase in phosphorylation during that physiological period [18,19]. We confirm here by means of Western blot the presence of p-Tau in the skin showing a similar molecular weight as in other organs [20-22]. The presence of p-Tau in the skin provides thus relevant information, and in our model AT8 (S202) immunoreactivity was significantly associated with the presence of AD.

The skin opens interesting possibilities for the study of neurodegenerative diseases because it is highly innervated and has the capacity of producing and releasing several neuropeptides [23]. It also expresses genes involved in neurological diseases like APP, Tau, PSEN1 and PARK2 among others [24]. According to this, several diseases from the nervous system have dermal manifestations, as it is the case of PD, where there is an increased risk of melanoma and patients present seborrhea and hyperhidrosis besides the classical motor manifestations of the disease [25].

In addition to becoming aggregated, Tau and other proteins that participate in neurodegenerative diseases translocate inside the cell nucleus [26,27] and interact with DNA [28, 29]. Current evidence supports that Tau participates in stress response protecting DNA [30,31], promotes chromosome stability by means of its interaction with both microtubules and chromatin [32], and upon DNA binding allows expression of silent genes immersed in heterochromatin [33]. These epigenetic changes however, are regarded as a source of neurodegeneration promoted by Tau, since it leads to the expression of aberrant genes in neurons. It is then of great interest that skin biopsies provide the possibility to explore Tau behavior in relation with epigenetic modifications.

Biomarkers of neurodegenerative diseases have been developed in recent years, mainly based on advanced molecular neuroimaging. Most health systems in the world, however, cannot afford these studies for the clinical practice. Therefore, skin biopsies represent an alternative to support the diagnosis of the two most important neurodegenerative diseases, by applying immunohistochemistry with commercially available antibodies. This can be done in a standard pathology lab of worldwide hospitals and clinical laboratories.

Acknowledgement

This study was funded by Consejo Nacional de Ciencia y Tecnología (CONACYT), Mexico, grant 201249 to MEJ. The authors thank H. Castillo from the Neurology Service, Central Hospital, San Luis Potosí, México, B. Torres Alvarez and JP Castanedo–Cazares from the Dermatology Department, Central Hospital, San Luis Potosí, México, for providing advice and training in the collection of biopsies, and I. Rodríguez-Moreno for reviewing the manuscript.
References

1. Iqbal K, Wang X, Blanchard J, Liu F, Gong CX, et al. (2010) Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans 38: 962-966.

2. Lee SJ, Lim HS, Masliah E, Lee HJ (2011) Protein aggregate spreading inneurodegenerative diseases: problems and perspectives. Neurosci Res 70: 339-348.

3. Gotz J, Matamala M, Gotz NN, Ittner LM, Eckert A (2012) Alzheimer's disease models and functional genomicst:How many needles are there in the haystack? Front Physiol 3: 320.

4. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204-1222.

5. Trojanowski JQ, Lee VM (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55: 151-152.

6. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, et al. (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 169: 1343-1352.

7. Pouclet H, Lebouvier T, Coron E, Rouaud T, Flamant M et al. (2012) Biopsable neural tissues: toward new biomarkers for Parkinson's disease. Front Psychiatry 1: 128.

8. Rodriguez-Leyva I, Calderon-Garcidueñas AL., Medina-Mier V et al. (2015) Presence of Phosphorylated Tau Protein in the Skin of Alzheimer’s Disease Patients. J Mol Biomark Diagn S6: S6-005. doi:10.4172/2155-9929.S6-005

9. Iqbal K, Wang X, Blanchard J, Liu F, Gong CX, et al. (2010) Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans 38: 962-966.

10. Lee SJ, Lim HS, Masliah E, Lee HJ (2011) Protein aggregate spreading inneurodegenerative diseases: problems and perspectives. Neurosci Res 70: 339-348.

11. Lebouvier T, Tasselli M, Paillusson S, Pouclet H, Neunlist M, et al. (2010) α-Synuclein and tau concentrations in cutaneous autonomic nerves. Neurology 81: 1604-1610.

12. Rodríguez-Leyva I, Calderón-Garcidueñas AL, Jiménez-Capdeville ME, Rentería-Palomo A, Hernández-Rodríguez HG, et al. (2014) α-Synuclein inclusions in the skin of Parkinson’s disease and parkinsonism. Ann Clin Transl Neurol 1: 471-478.

13. Wang N, Gibbons CH, Lafo J, Freeman R (2013) α-Synuclein in cutaneous autonomic nerves. Neurology 81: 1604-1610.

14. Doppler K, Ebert S, Ucejoler N, Trenkwalder C, Ebenthaluer J, et al. (2014) Cutaneouse neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol 128: 99-109.

15. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.

16. Daniel SE, Lees AJ (1993) Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39: 165-172.

17. Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-Aquino MC, Williams S (2014) Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol Appl Neurobiol 40: 121-135.

18. Arendt T, Stieler J, Striijkstra AM, Hut RA, Rüdiger J, et al. (2003) Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci 23: 6972-6981.

19. Stieler JT, Bullmann T, Kohl F, Tesien O, Brückner MK, et al. (2011) Thephysiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation. PLoS One 6: e14530.

20. Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9: 4225-4230.

21. Bullmann T, Holzer M, Mori H, Arendt T (2009) Pattern of tau isoforms expression during development in vivo. Int J Dev Neurosci 27: 591-597.

22. Clos AL, Kayed R, Lasagna-Reeves CA (2012) Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neuro 3: 5.

23. Makrantoni E, Brink TC, Zampeli V, Elewa RM, Moldy B, et al. (2012) Identification of biomarkers of human skin ageing in both genders. Wnt signalling - a label of skin ageing? PLoS One 7: e50393.

24. Antonini A, Barone P, Marconi R, Morgante L, Zappulla S, et al. (2012) The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 259: 2621-2631.

25. Lu J, Li T, He R, Bartlett PF, Gott J (2014) Visualizing the microtubule-associated protein tau in the nucleus. Sci China Life Sci 57: 422-431.

26. Zhou M, Xu S, Mi J, Ueda K, Chan P (2013) Nuclear translocation of α-synuclein increases susceptibility of MES23.5 cells to oxidative stress. Brain Res 1500: 19-27.

27. Camero S, Benitez MJ, Jimenez JS (2013) Anomalous protein-DNA interactions behind neurological disorders. Adv Protein Chem Struct Biol 91:37-63.

28. Sjögberg MK, Shestakova E, Mansuroğlu Z, Maccioni RB, Bonfey E (2006) Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J Cell Sci 119: 2025-2034.

29. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, et al. (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286: 4566-4575.

30. Camero S, Benitez MJ, Barrantes A, Ayuso JM, Cuadros R (2014) Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone DNA complex. J Alzheimers Dis 39: 649-660.

31. Rossi G, Dalprà L, Crosti F, Lissoni S, Sciacca FL (2008) A new function of microtubule-associated protein tau: involvement in chromosome stability. Cell Cycle 7: 1788-1794.

32. Frost B, Hemberg M, Lewis J, Feany MB (2014) Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci 17: 357-366.